ACR–ABS–ASTRO practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy

Harkenrider, Matthew M.; Albuquerque, Kevin; Brown, Derek; Kamrava, Mitchell; King, Martin T.; Mourtada, Firas; Orio, Peter F.; Patel, Rakesh; Price, Michael; Rassiah, Prema; Small, William; Schechter, Naomi R.

doi:10.1016/j.brachy.2021.08.009

Cited by 10 publications

(5 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…192 Ir is the most common radionuclide due to its combination of high penetration depth, relatively long half-life, and high specific activity. The Freiburg flap, Valencia, and Leipzig applicators are all used to treat superficial skin lesions while generic and modified (with interstitial needles) cylindrical applicators are used for treatment of cervical tumors [ 37 ]. Recently, Dupere and colleagues have proposed expanding the utilization of HDR brachytherapy by treating choroidal melanomas with an HDR 169 Yb source in conjunction with a gold shielded applicator.…”

Section: Brachytherapymentioning

confidence: 99%

Current and Emerging Radiotherapy Options for Uveal Melanoma

Semeniuk,

Yu,

Rivard

2024

Cancers

View full text Add to dashboard Cite

What treatment options are there for patients having uveal melanoma? A randomized, prospective, multi-institutional clinical trial (COMS) showed no difference in survival between brachytherapy and enucleation for medium-sized lesions. With the obvious benefit of retaining the eye, brachytherapy has flourished and many different approaches have been developed such as low-dose-rate sources using alternate low-energy photon-emitting radionuclides, different plaque designs and seed-loading techniques, high-dose-rate brachytherapy sources and applicators, and low- and high-dose-rate beta-emitting sources and applicators. There also have been developments of other radiation modalities like external-beam radiotherapy using linear accelerators with high-energy photons, particle accelerators for protons, and gamma stereotactic radiosurgery. This article examines the dosimetric properties, targeting capabilities, and outcomes of these approaches. The several modalities examined herein have differing attributes and it may be that no single approach would be considered optimal for all patients and all lesion characteristics.

show abstract

Section: Brachytherapymentioning

confidence: 99%

Current and Emerging Radiotherapy Options for Uveal Melanoma

Semeniuk,

Yu,

Rivard

2024

Cancers

View full text Add to dashboard Cite

show abstract

“…The reader is referred to ACR-ABS HDR and LDR practice parameters and the ASTRO HDR white paper, relating to LDR brachytherapy for prostate cancer and HDR brachytherapy: ACR-ABS-ASTRO Practice Parameter for the Performance of Low-Dose-Rate Brachytherapy, ACR-ABS-ASTRO Practice Parameter for the Performance of Radionuclide-Based High-Dose-Rate Brachytherapy, and ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer. [13][14][15][16] Stereotactic Radiosurgery SRS/SBRT may be used for certain benign or malignant intracranial and extracranial lesions. The reader is referred to ACR practice parameters and the ASTRO white paper relating to SRS and SBRT ACR-ARS Practice Parameter for the Performance of Brain Stereotactic Radiosurgery and ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy.…”

Section: Brachytherapymentioning

confidence: 99%

“…(13) Treatment summary or a completion-of-therapy note. (14) Follow-up plan. (15) Documentation that the treatment record was checked before and weekly during treatment.…”

mentioning

confidence: 99%

ACR–ARS Practice Parameter for Radiation Oncology

Lo,

Chao,

Harris

et al. 2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Aim/Objectives/Background: This practice parameter was revised collaboratively by the American College of Radiology (ACR), and the American Radium Society. This practice parameter provides updated reference literature regarding radiation oncology practice and its key personnel. Methods: This practice parameter was developed according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters—Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the American Radium Society. Results: This practice parameter provides a comprehensive update to the reference literature regarding radiation oncology practice in general. The overall roles of the radiation oncologist, the Qualified Medical Physicist, and other specialized personnel involved in the delivery of external-beam radiation therapy are discussed. The use of radiation therapy requires detailed attention to equipment, patient and personnel safety, equipment maintenance and quality assurance, and continuing staff education. Because the practice of radiation oncology occurs in a variety of clinical environments, the judgment of a qualified radiation oncologist should be used to apply these practice parameters to individual practices. Radiation oncologists should follow the guiding principle of limiting radiation exposure to patients and personnel while accomplishing therapeutic goals. Conclusions: This practice parameter can be used as an effective tool to guide radiation oncology practice by successfully incorporating the close interaction and coordination among radiation oncologists, medical physicists, dosimetrists, nurses, and radiation therapists.

show abstract

“…See the ACR-ABS Practice Parameter for the Performance of Radionuclide-Based High-Dose-Rate Brachytherapy. 19…”

Section: Patient Evaluation During Temporary Implantsmentioning

confidence: 99%

“…The use of HDR brachytherapy is covered in the ACR-ABS-ASTRO Practice Parameter for the Performance of Radionuclide-Based High-Dose-Rate Brachytherapy. 2 Despite different nomenclature, these types of brachytherapy have many common treatment principles. The types of applicators, methods of insertion, and many aspects of treatment planning are similar or even identical for LDR, PDR, and HDR.…”

Section: Introductionmentioning

confidence: 99%

ACR-ABS-ASTRO Practice Parameter for the Performance of Low-Dose-Rate Brachytherapy

Woodhouse

Devlin

Lin

et al. 2022

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Aim/Objectives/Background: The American College of Radiology (ACR), the American Brachytherapy Society (ABS), and the American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for the performance of low-dose-rate (LDR) brachytherapy. LDR brachytherapy is the application of radioactive sources in or on tumors in a clinical setting with therapeutic intent. The advantages of LDR brachytherapy include improving therapeutic ratios with lower doses to nontarget organs-at-risk and higher doses to a specific target.

show abstract

ACR–ABS–ASTRO practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy

Cited by 10 publications

References 101 publications

Current and Emerging Radiotherapy Options for Uveal Melanoma

Current and Emerging Radiotherapy Options for Uveal Melanoma

ACR–ARS Practice Parameter for Radiation Oncology

ACR-ABS-ASTRO Practice Parameter for the Performance of Low-Dose-Rate Brachytherapy

Contact Info

Product

Resources

About